News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
194,352 Results
Type
Article (19252)
Company Profile (109)
Press Release (174991)
Section
Business (63436)
Career Advice (806)
Deals (8932)
Drug Delivery (68)
Drug Development (18542)
Employer Resources (137)
FDA (3291)
Job Trends (5950)
News (94464)
Policy (6990)
Tag
Academia (1483)
Alliances (17145)
Alzheimer's disease (483)
Antibody-drug conjugate (ADC) (46)
Approvals (3260)
Artificial intelligence (72)
Bankruptcy (46)
Best Places to Work (4824)
Biosimilars (40)
Biotechnology (67)
Breast cancer (37)
Cancer (328)
Cardiovascular disease (40)
Career advice (711)
Cell therapy (91)
Clinical research (13744)
Collaboration (189)
COVID-19 (940)
C-suite (55)
Data (343)
Diabetes (45)
Diagnostics (2297)
Drug pricing (39)
Earnings (14146)
Employer resources (117)
Events (28778)
Executive appointments (158)
FDA (3426)
Funding (160)
Gene therapy (70)
GLP-1 (279)
Government (1291)
Healthcare (4875)
Infectious disease (978)
Inflammatory bowel disease (45)
Interviews (112)
IPO (3555)
Job creations (1295)
Job search strategy (628)
Layoffs (143)
Legal (1164)
Lung cancer (59)
Management (41)
Manufacturing (82)
Medical device (2564)
Medtech (2568)
Mergers & acquisitions (5459)
Metabolic disorders (153)
Neuroscience (590)
NextGen Class of 2024 (2073)
Non-profit (1664)
Northern California (466)
Obesity (102)
Opinion (87)
People (26454)
Phase I (4059)
Phase II (5687)
Phase III (5459)
Pipeline (116)
Postmarket research (556)
Preclinical (2334)
Press Release (61)
Radiopharmaceuticals (59)
Rare diseases (72)
Real estate (2501)
Recruiting (53)
Regulatory (4882)
Research institute (1254)
Resumes & cover letters (106)
Southern California (309)
Startups (1987)
United States (3940)
Vaccines (163)
Weight loss (83)
Date
Today (42)
Last 7 days (254)
Last 30 days (1077)
Last 365 days (11595)
2024 (10592)
2023 (12949)
2022 (15520)
2021 (17634)
2020 (16245)
2019 (14946)
2018 (10795)
2017 (10276)
2016 (10149)
2015 (10839)
2014 (7987)
2013 (6914)
2012 (7344)
2011 (7528)
2010 (7015)
Location
Africa (321)
Arizona (53)
Asia (11016)
Australia (1929)
California (928)
Canada (388)
China (77)
Colorado (51)
Europe (28308)
Florida (126)
Illinois (91)
Indiana (87)
Maryland (128)
Massachusetts (788)
Michigan (64)
Minnesota (86)
New Jersey (309)
New York (366)
North Carolina (231)
Northern California (466)
Ohio (46)
Pennsylvania (157)
South America (389)
Southern California (309)
Texas (130)
Washington State (85)
194,352 Results for "alimera sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Alimera Sciences Reports First Quarter 2024 Results
Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.
May 14, 2024
·
11 min read
Deals
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc. announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
June 24, 2024
·
17 min read
BioMidwest
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
Alimera Sciences, Inc. announced that, pursuant to Nasdaq Listing Rule 5635 and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company approved, on May 22, 2024, inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan.
June 4, 2024
·
1 min read
Press Releases
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
September 16, 2024
·
2 min read
Press Releases
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
September 16, 2024
·
13 min read
Press Releases
ANI Pharmaceuticals and Alimera Sciences Announces Closing Date of Merger
September 11, 2024
·
3 min read
Business
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
September 11, 2024
·
3 min read
Press Releases
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
September 10, 2024
·
1 min read
Business
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Alimera Sciences, Inc. today announced financial results for the fourth quarter and full year 2023.
March 7, 2024
·
16 min read
Business
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that it will report first quarter financial results on May 14, 2024, prior to the market open.
April 30, 2024
·
1 min read
1 of 19,436
Next
